{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:25Z","timestamp":1777934545082,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:00:00Z","timestamp":1613779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Oncopeptides"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Real-world evidence on later line treatment of relapsed\/refractory multiple myeloma (RRMM) is sparse. We evaluated clinical outcomes among RRMM patients in the 1-year following treatment with pomalidomide or daratumumab and compared economic outcomes between RRMM patients and non-MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient and Methods<\/jats:title>\n                    <jats:p>Adult patients with \u22651 claim of pomalidomide or daratumumab were identified between January 2012 and February 2018 using IQVIA PharMetrics\u00ae Plus US claims database. Patients were required to have a diagnosis or treatment for MM and a claim of any immunomodulatory drugs and proteasome inhibitors before the index date. Mean time to new therapy, overall survival (OS) using Kaplan-Meier curve and adverse events (AEs) were reported over the 1-year post-index period. RRMM patients were also matched to a non-MM comparator cohort and economic outcomes were compared between the two cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>289 RRMM patients were matched to 1,445 patients without MM. Most prevalent hematological AE was anemia (72.0%) and non-hematological AE was infections (75.4%). Mean (SD) time to a new treatment was 4.7 (5.3) months and median OS was 14.6\u2009months. RRMM patients had significantly higher hospitalizations and physician office visits (Both P\u2009&lt;\u2009.0001) compared to non-MM patients. Adjusting for baseline characteristics, patients with RRMM had 4.9 times (95% CI 3.8-6.4, P\u2009&lt;\u2009.0001) the total healthcare costs compared with patients without MM. The major driver of total costs among RRMM patients was pharmacy costs (67.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RRMM patients showed a high frequency of AEs, low OS, and a substantial economic burden suggesting need for effective treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155221995532","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:36:29Z","timestamp":1613954189000},"page":"395-409","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment patterns in relapsed\/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"Tisch Cancer institute at Mount Sinai Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamshi Ruthwik","family":"Anupindi","sequence":"additional","affiliation":[{"name":"IQVIA, Falls Church, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Yeaw","sequence":"additional","affiliation":[{"name":"IQVIA, Falls Church, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneel","family":"Kudaravalli","sequence":"additional","affiliation":[{"name":"Oncopeptides Inc, Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stojan","family":"Zavisic","sequence":"additional","affiliation":[{"name":"Oncopeptides AB, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drishti","family":"Shah","sequence":"additional","affiliation":[{"name":"IQVIA, Falls Church, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"key":"bibr1-1078155221995532","unstructured":"Myeloma MCM. Mayo Clinic. Multiple myeloma, https:\/\/www.mayoclinic.org\/diseases-conditions\/multiple-myeloma\/multimedia\/multiple-myeloma-infographic\/ifg-20442998 (accessed 12 February 2021)."},{"key":"bibr2-1078155221995532","unstructured":"American Society of Clinical Oncology (ASCO). Multiple myeloma: statistics, www.cancer.net\/cancer-types\/multiple-myeloma\/statistics (accessed 5 January 2020)."},{"key":"bibr3-1078155221995532","unstructured":"Oncology ASoC.\n                      Multiple myeloma statistics\n                      . Alexandria: American Society of Clinical Oncology,  https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about.html (accessed 12 February 2021)."},{"key":"bibr4-1078155221995532","unstructured":"Society AC.\n                      Key statistics about multiple myeloma\n                      . Atlanta: American Cancer Society."},{"key":"bibr5-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.76"},{"key":"bibr6-1078155221995532","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183475"},{"key":"bibr7-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"bibr8-1078155221995532","unstructured":"Leonard CFC, MaCurdy T, et\u00a0al. Utilization and cost of anticancer biologic products among Medicare beneficiaries, 2006\u20132009.\n                      Agency for Healthcare Research and Quality.\n                      (#6), https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65148\/pdf\/Bookshelf_NBK65148.pdf (accessed 12 February 2021)."},{"key":"bibr9-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"bibr10-1078155221995532","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01228"},{"key":"bibr11-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"bibr12-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"bibr13-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568923"},{"key":"bibr14-1078155221995532","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148882"},{"key":"bibr15-1078155221995532","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0049"},{"key":"bibr16-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1031732"},{"key":"bibr17-1078155221995532","first-page":"S59","volume":"4","author":"Kenney J.","year":"2011","journal-title":"Am Health Drug Benefits"},{"key":"bibr18-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0229"},{"key":"bibr19-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"bibr20-1078155221995532","doi-asserted-by":"crossref","unstructured":"Parikh K, Clancy Z, Zhou Z-Y, et\u00a0al.\n                      Novel treatment (Tx) use and associated outcomes among African American patients (pts) with multiple myeloma (MM): a SEER-Medicare analysis\n                      . Alexandria: American Society of Clinical Oncology, 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.e20030"},{"key":"bibr21-1078155221995532","first-page":"236","volume":"23","author":"Chen C-C","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr22-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24781"},{"key":"bibr23-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682518"},{"key":"bibr24-1078155221995532","author":"Lee HS","journal-title":"Am J Hematol"},{"key":"bibr25-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"bibr26-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"bibr27-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.467"},{"key":"bibr28-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0104"},{"key":"bibr29-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.31"},{"key":"bibr30-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"bibr31-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24883"},{"key":"bibr32-1078155221995532","first-page":"87","volume":"6","author":"Harvey RD.","year":"2014","journal-title":"Clin Pharmacol: Adv Appl"},{"key":"bibr33-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130791"},{"key":"bibr34-1078155221995532","first-page":"293","volume":"10","author":"Usami E","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"bibr35-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"bibr36-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0040-1"},{"key":"bibr37-1078155221995532","first-page":"204","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"bibr38-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361035"},{"key":"bibr39-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.048"},{"key":"bibr40-1078155221995532","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155221995532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155221995532","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155221995532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:14Z","timestamp":1777688774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155221995532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,20]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/1078155221995532"],"URL":"https:\/\/doi.org\/10.1177\/1078155221995532","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,20]]}}}